GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms

GSK logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • GSK expects sales to exceed £40 billion by 2031, up from about £35 billion this year, as new medicines and business growth offset upcoming patent expirations; the outlook depends on execution.
  • U.S. patents for HIV drugs Tivicay and Triumeq expire in 2028, with Dovato following in 2029; GSK expects the HIV business to decline most in 2029–30, partly offset by long-acting treatments in development.
  • GSK sees oncology as a major growth driver and says it retains capacity for further acquisitions. It also plans £1.9 billion in cost savings by 2029, with most savings reinvested in R&D.
  • Five stocks to consider instead of GSK.

GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference.

Redfern said the company expects sales to exceed £40 billion in 2031, compared with approximately £35 billion this year. He acknowledged that execution will be important as GSK manages patent expirations and advances its drug pipeline.

HIV patent losses and long-acting treatments

Redfern said U.S. patent protection for HIV medicines Tivicay and Triumeq is due to expire in April 2028, followed by Dovato at the end of 2029. He said European expirations also occur in 2029.

GSK expects its HIV business to decline to some degree in 2028, with the main declines in 2029 and 2030, he said. Growth in long-acting treatments should offset some, but not all, of the decline in oral medicines.

Through its ViiV business, GSK is developing longer-acting versions of HIV treatments. Redfern said the pivotal CUATRO study of a four-month version of Cabenuva has completed recruitment, with data expected in the second half of next year. The treatment could potentially reach the market in 2028, he said.

ViiV is also studying an investigational integrase inhibitor known as 184 alongside its own capsid inhibitor as a potential six-month regimen. Both are in Phase 2 studies, and Redfern said pivotal studies could begin around mid-2028, potentially leading to a launch in the early 2030s.

For HIV prevention, Redfern said GSK has data on a four-month version of Apretude and is discussing it with regulators. He said the company is confident in the formulation but did not provide further details.

Deal capacity and oncology ambitions

GSK has room for more acquisitions despite its recent purchases, Redfern said. He cited expected cash flow from operations of more than £10 billion this year and leverage of approximately 1.8 times. The company wants to maintain an A2 credit rating, he added.

Redfern said most deals before the acquisition of precision oncology company Nuvalent were typically in the $2 billion to $3 billion range. He said GSK likes that size, although dealmaking decisions also depend on profit-and-loss and management capacity.

The Nuvalent acquisition gave GSK an entry into lung cancer, Redfern said. He also highlighted antibody-drug conjugates licensed from Hansoh, including a B7-H3 treatment being studied in small cell lung cancer. GSK could potentially file for that treatment as early as next year, he said. Five pivotal studies are running for a B7-H4 treatment in ovarian and endometrial cancers.

Redfern said GSK’s oncology business generates about £2 billion today and that he hopes it will be materially larger and fast-growing in five years.

Restructuring and growth outlook

GSK plans to remove £1.9 billion in costs by 2029, with most of the savings reinvested in research and development, Redfern said. The restructuring spans the business, including opportunities to address older manufacturing sites, consolidate service centers and increase automation.

Redfern said GSK will move its research and development operations from Stevenage to Cambridge over the next two years. Most Stevenage employees will move to Cambridge, while a smaller number will move to the company’s site in Ware, he said.

Looking beyond the dolutegravir patent expirations, Redfern said the pipeline could help GSK accelerate growth in the early 2030s. He pointed to oncology, respiratory, liver disease, HIV and vaccine programs, while cautioning that the outlook depends on execution.

About GSK (NYSE:GSK)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GSK Right Now?

Before you consider GSK, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.

While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines